Swedish biotech company Salipro Biotech has entered into a research collaboration with Sumitomo Pharma to reveal the mechanism of action and pharmacological characteTrisation of a drug candidate.
Under the terms of the collaboration, Salipro Biotech will utilise its unique expertise in stabilising challenging membrane proteins such as GPCRs, ion channels and transporters via its proprietary Salipro technology platform to advance a Sumitomo Pharma’s drug discovery programme by characterising a drug candidate with the desired therapeutic properties against a selected target.
“We are excited to be working with Sumitomo Pharma to investigate this drug candidate and its mechanism of action,” said Jens Frauenfeld, CEO of Salipro Biotech. “Our distinct expertise and proprietary technology platform unlock novel drug targets that were previously considered too challenging to identify. By combining our expertise with Sumitomo Pharma’s advanced capabilities in CNS drug discovery and development, we aim to shed light on the therapeutic potential of a drug candidate.”
“Collaborating with Salipro Biotech represents an exciting opportunity to accelerate our understanding of the mechanism of action of our novel drug candidate,” said Isao Shimizu, Executive Officer of Sumitomo Pharma. “We look forward to working together to investigate its pharmacological characteristics.”
Collaborating with Salipro Biotech represents an exciting opportunity to accelerate our understanding of the mechanism of action
- Isao Shimizu, Executive Officer of Sumitomo Pharma
Salipro Biotech is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro platform technology for the stabilisation of membrane proteins.
To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech accelerates the discovery of novel drugs.
